Evaluation of BNT162b2 Vaccine Effectiveness in Galicia, Northwest Spain

Jacobo Pardo-Seco, Narmeen Mallah, Luis Ricardo López-Pérez, Juan Manuel González-Pérez, Benigno Rosón, María Teresa Otero-Barrós, Carmen Durán-Parrondo, Carmen Rodríguez-Tenreiro, Irene Rivero-Calle, Alberto Gómez-Carballa, Antonio Salas and Federico Martinón-Torres
Additional contact information
Jacobo Pardo-Seco: Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidad de Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
Narmeen Mallah: Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidad de Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
Luis Ricardo López-Pérez: Subdirección de Sistemas y Tecnologías de la Información, Servizo Galego de Saúde, 15703 Santiago de Compostela, Spain
Juan Manuel González-Pérez: Subdirección de Sistemas y Tecnologías de la Información, Servizo Galego de Saúde, 15703 Santiago de Compostela, Spain
Benigno Rosón: Subdirección de Sistemas y Tecnologías de la Información, Servizo Galego de Saúde, 15703 Santiago de Compostela, Spain
María Teresa Otero-Barrós: Dirección Xeral de Saúde Pública, Consellería de Sanidade, 15703 Santiago de Compostela, Spain
Carmen Durán-Parrondo: Dirección Xeral de Saúde Pública, Consellería de Sanidade, 15703 Santiago de Compostela, Spain
Carmen Rodríguez-Tenreiro: Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidad de Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
Irene Rivero-Calle: Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidad de Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
Alberto Gómez-Carballa: Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidad de Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
Antonio Salas: Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidad de Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
Federico Martinón-Torres: Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidad de Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain

IJERPH, 2022, vol. 19, issue 7, 1-11

Abstract: Investigating vaccine effectiveness (VE) in real-world conditions is crucial, especially its variation across different settings and populations. We undertook a test-negative control study in Galicia (Northwest Spain) to assess BNT162b2 effectiveness against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as well as COVID-19 associated hospitalization, intensive care unit (ICU) admission and mortality. A total of 44,401 positive and 817,025 negative SARS-CoV-2 test results belonging to adults were included. Adjusted odds ratios of vaccination and their 95% confidence interval (CI) were estimated using multivariate logistic-regression models. BNT162b2 showed high effectiveness in reducing SARS-CoV-2 infections in all age categories, reaching maximum VE ≥ 14 days after administering the second dose [18–64 years: VE = 92.9% (95%CI: 90.2–95.1); 65–79 years: VE = 85.8% (95%CI: 77.3–91.9), and ≥80 years: VE = 91.4% (95%CI: 87.9–94.1)]. BNT162b2 also demonstrated effectiveness in preventing COVID-19 hospitalization for all age categories, with VE more pronounced for those aged ≥80 years [VE = 60.0% (95%CI: 49.4–68.3)]. Moreover, there was a considerable reduction in ICU admission [VE = 88.0% (95%CI: 74.6–95.8)] and mortality [VE = 38.0% (95%CI: 15.9–55.4)] in the overall population. BNT162b2 showed substantial protection against SARS-CoV-2 infections and COVID-19 severity. Our findings would prove useful for systematic reviews and meta-analysis on COVID-19 VE.

Keywords: SARS-CoV-2; COVID-19; vaccine effectiveness; population study (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/7/4039/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/7/4039/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:7:p:4039-:d:782064

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().